Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 10—October 2015
Research

Epidemiology of Lyme Disease, Nova Scotia, Canada, 2002–2013

Todd F. HatchetteComments to Author , B. Lynn Johnston, Emily Schleihauf, Angela Mask, David Haldane, Michael Drebot, Maureen Baikie, Teri Cole, Sarah Fleming, Richard Gould, and Robbin Lindsay
Author affiliations: Nova Scotia Health Authority, Halifax, Nova Scotia, Canada (T.F. Hatchette, B.L. Johnston, D. Haldane); Dalhousie University, Halifax (T.F. Hatchette, B.L. Johnston, D. Haldane); Public Health Agency of Canada, Ottawa, Ontario, Canada (E. Schleihauf, A. Mask); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (M. Drebot, R. Lindsay) Government of Nunavut, Iqaluit, Nunavut, Canada (M. Baikie); Nova Scotia Department of Health and Wellness, Halifax (T.J. Cole, S. Fleming); York Region Public Health, Newmarket, Ontario, Canada (R. Gould)

Main Article

Table 4

LD test results from serosurvey and seroprevalence estimates, Nova Scotia, Canada, 2002–2013*

Region (no. endemic regions) Laboratory test type
 Seroprevalence estimate
Total screening tests, whole-cell EIA Whole-cell EIA positive or indeterminate, no. (%) C6 positive or equivocal, no. (%) IgG WB borderline, no. (%) IgG WB borderline, % (95% CI) C6 ELISA, %, (95% CI)
DHA 1 (2) 191 21 (11.0) 1 (0.5) 0 0 (0–1.9) 0.52 (0–2.9)
DHA 2 (2) 199 19 (9.5) 2 (1.0) 0 0 (0–1.8) 1.01 (0.1–3.6)
DHA 3 261 42 (16.1) 2 (0.8) 0 0 (0–1.4) 0.77 (0.1–2.7)
DHA 4 120 12 (10.0) 1 (0.8) 1 (0.8) 0.83 (0–4.6) 0.83 (0–4.6)
DHA 5 44 1 (2.3) 1 (2.3) 0 0 (0–8.0) 2.27 (0.1–12.0)
DHA 6 (1) 74 3 (4.1) 0 0 0 (0–4.9) 0 (0–4.9)
DHA 7 72 3 (4.2) 0 0 0 (0–5.0) 0 (0–5.0)
DHA 8 201 22 (10.9) 1 (0.5) 0 0 (0–1.8) 0.5 (0–2.7)
DHA 9 (1)
 693
 92 (13.3)
 9 (1.3)
 1 (0.1)
0.14 (0–0.8)
 1.3 (0.6–2.5)
Nova Scotia† 1,855 215 (11.6) 17 (0.9) 2 (0.1) 0.14 (0.02–0.51) 0.98 (0.56–1.60)

*DHA, District Health Authority; EIA, enzyme immunoassay; LD, Lyme disease; WB, Western blot.
†Provincial seroprevalence estimates weighted by age, sex, and DHA, accounting for oversampling in DHAs 1, 2, and 3.

Main Article

Page created: September 22, 2015
Page updated: September 22, 2015
Page reviewed: September 22, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external